What's in Università degli Studi di Brescia's pipeline?

Università degli Studi di Brescia has 12 drugs in our index: 8 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Università degli Studi di Brescia's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Actavis Inc., Assaf-Harofeh Medical Center, Allergy and Asthma Center of El Paso, Amneal Pharmaceuticals, LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universit-degli-studi-di-brescia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Università degli Studi di Brescia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Università degli Studi di Brescia pipeline: 8 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pranoprofen Eyedrops	Pranoprofen Eyedrops	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)	Ophthalmology
Dinoprostone vaginal pessary	Dinoprostone vaginal pessary	marketed	Prostaglandin F2α analog	Prostaglandin F (FP) receptor	Obstetrics
Salmeterol Fluticasone	Salmeterol Fluticasone	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)	Respiratory/Pulmonology
mixture of amino and keto acids	mixture of amino and keto acids	marketed
Nepafenac 0.1% eyedrops	Nepafenac 0.1% eyedrops	marketed
formoterol - beclometasone	formoterol - beclometasone	marketed
Omega-3 Supplementation	Omega-3 Supplementation	marketed	Dietary supplement / Lipid-modifying agent	GPR120, GPR40, PPAR-γ, NF-κB signaling pathway	Cardiovascular
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)	Ophthalmology
n-3 PUFAs	n-3 PUFAs	phase 3	Fatty acid		Cardiovascular
Ketorolac 0.5% eyedrops	Ketorolac 0.5% eyedrops	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)	Ophthalmology
Bromfenac 0.09% eyedrops	Bromfenac 0.09% eyedrops	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)	Ophthalmology
Indomethacin 0.5% eyedrops	Indomethacin 0.5% eyedrops	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)	Ophthalmology

Therapeutic area mix

Ophthalmology · 5
Cardiovascular · 2
Obstetrics · 1
Respiratory/Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Actavis Inc. · 1 shared drug class
Assaf-Harofeh Medical Center · 1 shared drug class
Allergy and Asthma Center of El Paso · 1 shared drug class
Amneal Pharmaceuticals, LLC · 1 shared drug class
Amzell · 1 shared drug class
Allergy & Asthma Medical Group & Research Center · 1 shared drug class
Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Università degli Studi di Brescia:

Cite this brief

Drug Landscape (2026). Università degli Studi di Brescia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-degli-studi-di-brescia. Accessed 2026-05-17.